Exhibit 99.1

AAC Holdings, Inc. Reports Fourth Quarter and Full Year 2015 Results

BRENTWOOD, Tenn. – (February 23, 2016) AAC Holdings, Inc. (NYSE: AAC) announced its results for the fourth quarter and year ended December 31, 2015. All comparisons included in this release are to the comparable prior year period unless otherwise noted.

Fourth Quarter and Full Year 2015 Financial Highlights:

De Novo and Acquisition Highlights:

Fourth Quarter 2015

Revenues in the fourth quarter of 2015 increased to $58.3 million compared with $37.2 million in the prior-year period and $57.4 million in the third quarter of 2015. Adjusted EBITDA increased to $9.4 million compared with $6.6 million in the prior-year period and down from $11.7 million in the third quarter of 2015. Adjusted net income available to stockholders increased to $3.8 million, or

$0.17 per diluted share, compared with $4.3 million, or $0.20 per diluted share, in the prior-year period and down from $6.0 million, or $0.27 per diluted share, in the third quarter of 2015. Net income available to stockholders was $0.5 million, or $0.02 per diluted share, in the fourth quarter of 2015 compared with $3.1 million, or $0.15 per diluted share, in the prior-year period and $2.5 million, or $0.11 per diluted share, in the third quarter of 2015. Adjusted net income available to stockholders and Adjusted EBITDA are non-GAAP financial measures. Tables reconciling these measures to net income available to stockholders and net income, respectively, are included in this release.

As anticipated, revenue from our ancillary services in the fourth quarter of 2015, which includes point-of-care drug testing, definitive laboratory services, professional groups and other ancillary services, declined to 22% of total client related revenue compared with 26% in the prior-year period and 26% in the third quarter of 2015.

“We ended 2015 on a strong pace for new admissions, residential census, outpatient visits, and acquisitions under contract,” noted Michael Cartwright, Chairman and Chief Executive Officer of AAC Holdings. “Our focus on clinical quality and a vision for addressing this national epidemic continue to attract top staff as well as many other treatment providers who want to join the AAC family. We have much needed inpatient, outpatient and sober living capacity coming online through de novo, acquisition and organic growth as well as expanded marketing and lab capabilities. We expect 2016 to be a pivotal year for establishing our national platform.”

Year Ended December 31, 2015

Revenues for 2015 increased to $212.3 million compared with $133.0 for 2014. Adjusted EBITDA increased to $44.3 million compared with $21.1 million for 2014. Adjusted net income available to stockholders increased to $20.9 million, or $0.97 per diluted share, compared with $8.7 million, or $0.52 per diluted share, for 2014. Net income available to stockholders increased to $10.5 million, or $0.48 per diluted share, compared with $6.9 million, or $0.41 per diluted share, for 2014.

De Novo Activity and Pipeline

Renovations at Laguna Treatment Hospital, the Company’s 93-bed Chemical Dependency Rehabilitation Hospital near Laguna Beach, California, are nearing completion. The hospital is currently expected to open in the second quarter of 2016.

In October, the Company began treating clients at River Oaks, the 162-bed, $18.8 million residential facility near Tampa, Florida with current census at 100, or 91% of the 110 staffed beds.

The Company has initiated the development of 22 additional detoxification beds at its Recovery First facility in Fort Lauderdale, Florida, that are currently expected to come online in the fourth quarter of 2016, and has initiated the development of 44 additional residential beds and 48 sober living beds at The Oxford Centre in Mississippi that are currently expected to come online in the first half of 2017.

Acquisition Activity

In October, the Company completed the acquisition of the assets of Sunrise House Foundation, Inc., the operator of a 110-bed substance abuse treatment center, 30 halfway house beds and two outpatient programs all in Western New Jersey, for a purchase price of $6.6 million in cash.

In December, the Company signed a definitive agreement to acquire Townsend, a substance abuse treatment provider in Louisiana that operates six in-network outpatient centers that deliver intensive outpatient treatment, a 32-bed in-network facility that offers detoxification and inpatient treatment and an in-network lab that services its facilities for a purchase price of $12.75 million in cash and $8.5 million in restricted shares of the Company’s common stock. This transation is currently anticipated to close in the first half of 2016.

In December, the Company also signed a definitive agreement to acquire Las Vegas-based Solutions Recovery, its affiliates and real estate assets for $6.75 million cash and $6.25 million of restricted shares of the Company’s common stock. The acquisition, which is expected to close in the first half of 2016, subject to customary closing conditions, will provide 124 sober living beds, 70 licensed in-network detoxification, residential and halfway house beds, and three in-network outpatient centers.

Balance Sheet and Cash Flows from Operations

As of December 31, 2015, AAC Holdings’ balance sheet reflected cash and cash equivalents of $18.8 million and total debt of $145.1 million. Capital expenditures in the fourth quarter of 2015 totaled $8.7 million. Cash flows provided by operations totaled $0.4 million for the fourth quarter of 2015 compared with cash flows provided by operations of $2.2 million in the prior-year period and cash flows used by operations of $0.8 million in the third quarter of 2015. Days sales outstanding (DSO) was 96 for the fourth quarter of 2015 compared with 71 for the prior-year period and 93 for the third quarter of 2015. For the months of December 2015 and January 2016, however, DSO declined to 89 and 85, respectively.

Deerfield Management Capital Commitment

As of December 31, 2015, the Company had drawn down $25.0 million of convertible subordinated debt from affiliates of Deerfield Management Company, L.P. that bears interest at an annual rate of 2.5%, matures on September 30, 2021 and is convertible to common stock at $30.00 per share. AAC has undrawn capacity of up to an additional $25.0 million of subordinated debt and up to $50.0 million of subordinated convertible debt (subject to certain conditions).

2016 Outlook

For the full year 2016, revenues are expected to be in the range of $265 million to $275 million. This estimate is based on average daily residential census for the year of 800, inclusive of access to Laguna Treatment Hospital and additional beds at Recovery First; average daily residential revenue of approximately $800 to $825; and approximately $32 million to $34 million of revenue from standalone outpatient centers and related lab services from those visits, as well as from the Recovery Brands, Townsend and Solutions Recovery acquisitions.

Adjusted EBITDA is expected to be in the range of $52 million to $55 million and adjusted earnings per diluted share is expected to be in the range of $0.95 to $1.03. Assumptions also include an annual effective tax rate of 37% to 39% and diluted weighted-average shares outstanding of approximately 23 million for the year.

This outlook does not include the impact of any future acquisitions, transaction-related costs, litigation settlement, expenses related to legal defenses and de novo start-up expenses.

Earnings Conference Call

The Company will host a conference call and live audio webcast, both open for the general public to hear, on Tuesday, February 23, 2016, at 10:00 a.m. CT. The number to call for this interactive teleconference is (412) 542-4144. A replay of the conference call will be available through March 2, 2016, by dialing (412) 317-0088 and entering the replay access code: 10079603.

The live audio webcast of the Company’s quarterly conference call will be available online in the Investor Relations section of the Company’s website at www.americanaddictioncenters.com. The online replay will be available in the Investor Relations section of the Company’s website one hour after the call.

About American Addiction Centers

American Addiction Centers is a leading provider of inpatient substance abuse treatment services. We treat clients who are struggling with drug addiction, alcohol addiction, and co-occurring mental/behavioral health issues. We currently operate 18 substance abuse treatment facilities. Located throughout the United States, these facilities are focused on delivering effective clinical care and treatment solutions. For more information, please find us at AmericanAddictionCenters.org or follow us on Twitter @AAC_Tweet.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the federal securities laws. These forward-looking statements are made only as of the date of this release. In some cases, you can identify forward-looking statements by terms such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “may,” “potential,” “predicts,” “projects,” “should,” “will,” “would,” and similar expressions intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements may include information concerning AAC Holdings, Inc.’s (collectively with its subsidiaries; “Holdings” or the “Company”) possible or assumed future results of operations, including descriptions of Holdings’ revenues, profitability, outlook and overall business strategy. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results and performance to be materially different from the information contained in the forward-looking statements. These risks, uncertainties and other factors include, without limitation: (i) our inability to operate our facilities; (ii) our reliance on our sales and marketing program to continuously attract and enroll clients; (iii) a reduction in reimbursement rates by certain third-party payors for inpatient and outpatient services and point of care and definitive lab testing; (iv) our failure to successfully achieve growth through acquisitions and de novo expansions; (v) uncertainties regarding the timing of the closing of acquisitions; (vi) the possibility that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of acquisitions; (vii) our failure to achieve anticipated financial results from prior or pending acquisitions; (viii) a disruption in our ability to perform definitive drug testing services; (ix) maintaining compliance with applicable regulatory authorities, licensure and permits to operate our facilities and lab; (x) a disruption in our business related to the recent indictment of certain of our subsidiaries and current and former employees, including a former senior executive; (xi) our inability to agree on conversion and other terms for the balance of convertible debt; (xii) our inability to meet our covenants in the loan documents; (xiii) our inability to obtain senior lender consent to exceed the current $50 million limit in unsecured subordinated debt; (xiv) our inability to integrate newly acquired facilities; (xv) a disruption to our business and reputational and potential economic risks associated with the civil securities claims brought by shareholders; and (xvi) general economic conditions, as well as other risks discussed in the “Risk Factors” section of the Company’s Annual Report on Form 10-K, and other filings with the Securities and Exchange Commission. As a result of these factors, we cannot assure you that the forward-looking statements in this release will prove to be accurate. Investors should not place undue reliance upon forward looking statements.

AAC HOLDINGS, INC.

CONDENSED CONSOLIDATED INCOME STATEMENTS

Unaudited

(Dollars in thousands, except per share amounts)

AAC HOLDINGS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

Unaudited

(Dollars in thousands)

AAC HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

Unaudited

(Dollars in thousands)

AAC Holdings, Inc.

Operating Metrics

Unaudited

AAC Holdings, Inc.

Supplemental Reconciliation of Non-GAAP Disclosures

Unaudited

(Dollars in thousands, except per share amounts)

Reconciliation of Adjusted EBITDA to Net Income

Reconciliation of Adjusted Net Income Available to AAC Holdings, Inc. Common Stockholders to Net Income Available to AAC Holdings, Inc. Common Stockholders

Adjusted EBITDA, adjusted net income available to AAC Holdings, Inc. common stockholders, and adjusted diluted earnings per share (herein collectively referred to as “Non-GAAP Disclosures”) are “non-GAAP financial measures” as defined under the rules and regulations promulgated by the U.S. Securities and Exchange Commission.

Management defines Adjusted EBITDA as net income adjusted for interest expense, depreciation and amortization expense, income tax expense, stock-based compensation and related tax reimbursements, litigation settlement and California matter related expense, reorganization expense (which includes certain reorganization transactions completed in April 2014 (the “Reorganization Transactions”) and expenses associated with the amendment and restatement of our prior credit facility in April 2014), acquisition-related expense (which includes professional services for accounting, legal, valuation services and licensing expenses), de novo start-up expenses, facility closure operating losses and expense associated with The Academy and FitRx, and bargain purchase gain associated with our acquisition of Sunrise House in the fourth quarter of 2015.

Management defines Adjusted Net Income Available to AAC Holdings, Inc. common stockholders as net income available to AAC Holdings, Inc. common stockholders adjusted for litigation settlement and California matter related expense, reorganization expense (which includes certain reorganization transactions completed in April 2014 (the “Reorganization Transactions”) and expenses associated with the amendment and restatement of our prior credit facility in April 2014), acquisition-related expense (which includes professional services for accounting, legal, valuation services and licensing expenses), de novo start-up expenses, facility closure operating losses and expense associated with The Academy and FitRx, bargain purchase gain associated with our acquisition of Sunrise House in the fourth quarter of 2015, redemption of BHR Series A Preferred Units, and the income tax effect of the non-GAAP adjustments at the then applicable effective tax rate.

AAC Holdings, Inc.

Supplemental Reconciliation of Non-GAAP Disclosures (continued)

Unaudited

(Dollars in thousands, except per share amounts)

The following table presents Adjusted EBITDA, Adjusted Net Income Available to AAC Holdings, Inc. common stockholders, and Adjusted diluted earning per share as previously stated and as recast.

The Non-GAAP Disclosures are considered supplemental measures of the Company’s performance and are not required by, or presented in accordance with, generally accepted accounting principles, or GAAP. The Non-GAAP Disclosures are not measures of the Company’s financial performance under GAAP and should not be considered as an alternative to net income or any other performance measures derived in accordance with GAAP. Management has included information concerning Non-GAAP Disclosures because they believe that such information is used by certain investors as a measure of a company’s historical performance. Management believes these measures are frequently used by securities analysts, investors and other interested parties in the evaluation of issuers of equity securities, many of which present EBITDA and Adjusted EBITDA when reporting their results. Because Non-GAAP Disclosures are not determined in accordance with GAAP, they are subject to varying calculations and may not be comparable to similarly titled measures of other companies. Management’s presentation of Non-GAAP Disclosures should not be construed as an inference that our future results will be unaffected by unusual or nonrecurring items.